Use of Pristinamycin for Infections by Gram-Positive Bacteria: Clinical Experience at an Australian Hospital

Abstract

Thirty-six patients were treated with pristinamycin for 46 different microbiological isolates between April 2007 and July 2009. Pathogens included 9 methicillin-resistant Staphylococcus aureus isolates, 13 methicillin-resistant coagulase negative staphylococci, and 9 vancomycin-resistant enterococci. Sites of infections included 12 osteomyelitis cases, 10 prosthetic joints, 4 other prostheses, and 1 epidural abscess. Five patients ceased treatment due to side effects. Ten patients were cured of their infections, and 21 patients had infections successfully suppressed.

The prevention and management of infections due to multidrug resistant organisms in haematology patients

“…• In a retrospective review of 46 cases predominately suppression of VRE or staphylococci (58%) joint, bone or wound infections [152].…”

Current concepts in the management of prosthetic joint infection

“…For susceptible isolates, outcomes are reasonable with intravenous beta-lactams although only limited information is available for patients treated with DAR. 42 For continuing oral treatment of penicillinresistant enterococci after intravenous vancomycin, linezolid or pristinamycin have been used 30,33 and clindamycin has been used for streptococci. 40 Synergistic ceftriaxone has been given with penicillin with success in some patients.…”

“…There have been descriptions of fusidic acid interacting with statins and causing rhabdomyolysis. 29 Other oral antibiotics that have been used in combination with rifampicin for staphylococcal PJI in smaller numbers of patients with less success or more intolerance are pristinamycin, 30 trimethoprim/sulfamethoxazole 31 and minocycline. 32 There is good in vitro evidence that linezolid can prevent the emergence of rifampicin resistance and some clinical evidence that it can be used as a single agent for PJI where rifampicin cannot be used; however, its use is limited by the development of severe adverse effects, such as peripheral neuropathy, optic neuropathy and cytopenias, especially when used for longer than 4 weeks.…”

Design-driven, multi-use research agendas to enable applied synthetic biology for global health

“…1). p-AF is both the immediate chemical precursor of the pristinamycin family of antibiotics (Blanc et al 1997;Reid et al 2010) and novel compounds investigated as diabetes treatments (Duffy et al 2007). Several of the immediate chemical precursors of p-AF are themselves starting points for synthesizing potent analgesic compounds (Juminaga et al 2012).…”